Table 3.

Susceptibility of serial passaged HSV-2 SB5 isolates to PCV as measured by the PRA

Parental SB5a	Passage No.	PCV IC50 (μg/ml)
		Placebo	FCV	VCV
0.79	1	0.76 ± 0.08b	0.78 ± 0.05	0.87 ± 0.09
1.02	2	0.98 ± 0.08	0.82 ± 0.23	0.96 ± 0.27
1.06	3	1.10 ± 0.23	1.04 ± 0.22	0.87 ± 0.04
1.43	4	1.55 ± 0.15	1.02 ± 0.51	1.14 ± 0.58
1.11	5	1.32 ± 0.38	1.47 ± 0.48	1.14 ± 0.18
0.80	6	0.96 ± 0.18	0.81 ± 0.05	0.85 ± 0.16
0.90	7	0.81 ± 0.08	0.77 ± 0.05	0.82 ± 0.12

^aIC₅₀ against PCV for the original parental control virus preparation (not passaged in mice). ^bIC₅₀ against PCV ± standard deviation for test isolates for n = 5 samples.